(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

ClinicalTrials.gov ID: NCT04996875

Public ClinicalTrials.gov record NCT04996875. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 7, 2026, 12:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis

Study identification

NCT ID: NCT04996875
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Cogent Biosciences, Inc.; Industry
Enrollment: 140 participants

Conditions and interventions

Conditions

Interventions

bezuclastinib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 8, 2021
Primary completion: Sep 18, 2025
Completion: Jun 30, 2027
Last update posted: May 4, 2026

2021 – 2027

United States locations

U.S. sites: 14
U.S. states: 12
U.S. cities: 14

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham (UAB) Hospital	Birmingham	Alabama	35233	Active, not recruiting
Mayo Clinic Arizona	Phoenix	Arizona	85054	Recruiting
City of Hope Comprehensive Cancer Center	Duarte	California	91010	Recruiting
UCLA Medical Center	Los Angeles	California	90095	Recruiting
Stanford Cancer Institute	Stanford	California	94305	Recruiting
Galiz Research	Hialeah	Florida	33016	Withdrawn
Winship Cancer Institute - Emory University	Atlanta	Georgia	30322	Recruiting
Rush University Medical Center	Chicago	Illinois	60612	Withdrawn
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
Columbia University Irving Medical Center	New York	New York	10032	Withdrawn
Cleveland Clinic Taussig Cancer Center	Cleveland	Ohio	44106	Active, not recruiting
MUSC Health University Medical Center	Charleston	South Carolina	29425	Recruiting
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
Huntsman Cancer Institute - University of Utah Health	Salt Lake City	Utah	84112	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04996875, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 4, 2026 · Synced May 7, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04996875 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →